 STAMFORD, Conn., Nov. 11, 2020 GLOBE NEWSWIRE -- Cara Therapeutics, Inc. Nasdaq: CARA, a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced that Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer, will participate in the following upcoming virtual investor conferences and events in November and December: 